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Abstract: Our previous results showed that a single oral dose (1 or 20 mg/kg body weight) of the anti-addiction agent ibo-
gaine induced in rats 6 and 24 h after administration glycogenolytic activity in hepatocytes, followed by a mild oxidative 
stress. In this work, we examined the in vivo effect of the same doses of ibogaine on rat kidney morphology, antioxidant 
enzyme (superoxide dismutases (SOD1 and 2), catalase, glutathione peroxidase, glutathione reductase (GR) and glutathione-
S-transferase) activities, and oxidative stress (TBARS) and redox (-SH groups) parameters. The dose of 1 mg/kg ibogaine 
induced an elevation in SOD1 activity and decreased GR activity after 6 and 24 h. GR activity was decreased at 6 and 24 
h after 20 mg/kg ibogaine administration, suggesting changed redox homeostasis. After 24 h, we observed an increase 
in moderate morphological changes, without changes in urinalyses, indicating that kidney function was not measurably 
affected. Nevertheless, kidney-function monitoring during and following ibogaine use in human subjects is advisable.
Keywords: ibogaine; kidney; antioxidant enzymes; lipid peroxidation; proximal tubules
INTRODUCTION
Ibogaine, in addition to its traditional use in African 
tribal communities for spiritual purposes [1], has also 
been used as an anti-addictive agent [2,3]. For this pur-
pose, single doses, ranging from 1 to 25 mg/kg (given 
per os), have been suggested. The dose of 20 mg/kg has 
been found to be safe, but based on several safety fac-
tors, a maximum oral dosage limit of less than 1 mg/kg 
was suggested [4,5]. In our recent work, we showed that 
ibogaine at a single dose of either 1 or 20 mg/kg body 
weight (b.w.) per os caused depletion of liver glycogen 6 
and 24 h post treatment, suggesting extensive utilization 
of glucose. In addition, thiobarbituric acid reactive sub-
stances (TBARS) were elevated 6 h after application of 1 
mg/kg b.w., suggesting a mild prooxidant effect, but the 
increase was insufficient to promote a systemic change 
in hepatic antioxidant enzyme activities [6]. Previous 
in vitro findings showed that ibogaine affected cellular 
energy metabolism as it leads to the rapid discharge of 
ATP pools in yeast [7] and erythrocytes [8], which is 
associated with an increase in the amount of certain 
metabolic enzymes involved in glycolysis and Krebs 
cycle [9], reactive oxygen species (ROS) production 
and increased activities of antioxidative enzymes [10]. 
Therefore, ibogaine is considered a pro-antioxidant, 
although it does not possess antioxidant properties 
[11]. However, in vitro and ex vivo experiments were 
performed with much higher doses than those applied in 
vivo (after per os application), where its pro-antioxidant 
ability was not so convincingly shown. Results revealed 
that in vivo intragastric application in rats and mice led 
to much lower concentrations of ibogaine and its main 
metabolite, noribogaine, in blood plasma as compared 
to doses used in vitro [6,12].
In this work, we explored the in vivo effects of 
ibogaine, using doses already applied in our previous 
work (1 or 20 mg/kg b.w. per os, the effects of which 
were examined after 6 and 24 h [6]), on the activities of 
antioxidative enzymes: cytosolic copper-zinc superoxide 
dismutase (SOD1), mitochondrial manganese super-
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oxide dismutase (SOD2), catalase (CAT), glutathione 
peroxidase (GSH-Px), glutathione reductase (GR) and 
glutathione S-transferases (GST), after 6 and 24 h in rat 
kidney. We also measured the amounts of TBARS and 
-SH groups as markers of lipid peroxidation and the 
thiol-based redox state, respectively. Because ibogaine 
and its metabolite noribogaine are metabolized by the 
kidneys, we performed histological examination of 
the kidney cortex and basic urinalysis (red blood cells 
(RBC), white blood cells (WBC), glucose, bilirubin, 
ketones and nitrites, pH, specific density, protein, 
urobilinogen and ascorbic acid concentrations).
MATERIALS AND METHODS
Animals
All procedures complied with the EEC Directive on the 
protection of animals used for experimental and other 
scientific purposes and were approved by the Ethical 
Committee for the Use of Laboratory Animals of the 
Institute for Biological Research “Siniša Stanković”, 
University of Belgrade (decision No. 02-03/16). Three-
month-old male Wistar rats, body weight 305±15 g, 
were housed under standard laboratory conditions 
(light/dark 12/12 h, at 22°C). Water and food were 
available ad libitum.
Experimental design
Ibogaine hydrochloride (PubChem CID: 197059, 
purity 98.93%), was a kind gift from the Sacrament 
of Transition, Maribor, Slovenia, and from Remøgen, 
Phytostan Enterprises Inc., Canada (purity 99.9%), and 
was provided by M.B. from the LNPR project funded 
by the ARRS Program P3-0171. Ibogaine stock (dis-
solved in dH2O, concentration 2 mg/mL) was prepared 
fresh and protected from light till administration. The 
animals were randomly divided into three groups: 
control, ibogaine low dose (1 mg/kg b.w.), and ibogaine 
high dose (20 mg/kg b.w.). Each group was randomly 
divided into two subgroups to be decapitated after 6 
h or decapitated after 24 h. All animals received 1 mL 
of liquid (dH2O or ibogaine solution of appropriate 
concentration) per 100 g b.w. via intubation. The 
control group was treated with dH2O. The control 
group contained 6 animals (3 animals per subgroup), 
and the ibogaine-treated groups contained 12 animals 
per group (6 animals per subgroup). The design of the 
experiment was as follows: control groups Cont6 and 
Cont24; ibogaine (1 mg/kg b.w.) groups L6 and L24; 
ibogaine (20 mg/kg b.w.) groups H6 and H24. The 
numbers 6 and 24 indicate the times post ibogaine 
administration when the animals were killed.
Tissue preparation 
After decapitation, both kidneys were removed. The 
anterior part of the right kidney (one third of the kidney) 
was fixed in 4% paraformaldehyde (pH 7.4, 24 h). The 
left kidney and the rest of the right kidney tissue were 
frozen in liquid nitrogen and kept at -70°C until use.
Preparation of tissue and determination of 
enzyme activities
For determination of antioxidative enzyme and GST 
activities, kidney samples were homogenized (3x10 s, 
pause 10 s) and sonicated (3x15 s; 10 kHz, pause 15 
s) on ice in 0.25 M sucrose, 50 mM Tris, 1 mM EDTA 
buffer, pH 7.4, and centrifuged at 4°C, 105000 x g, for 
90 min. For determination of the concentrations of 
TBARS, total and non-protein -SH groups, sonicated 
homogenate prepared in non-sucrose buffer 50 mM 
Tris, 1 mM EDTA, pH 7.4, was centrifuged at room 
temperature at 9000 x g for 15 min. The activity of 
antioxidant enzymes were measured in supernatants 
spectrophotometrically. The activities of total SOD and 
SOD2 were determined by the adrenaline method [13]. 
For determination of SOD2, samples were incubated 
with 8 mM KCN at room temperature for 30 min. 
The activity of SOD1 was calculated as the difference 
between total SOD and SOD2 activities. One SOD 
unit (U) is defined as the amount of enzyme required 
to decrease the rate of adrenaline auto-oxidation by 
50% at pH 10.2. The activity of CAT was measured by 
monitoring H2O2 consumption at 230 nm, according to 
the method described by Beutler [14]. The activity of 
GSH-Px was determined according to the modified assay 
described by Paglia and Valentine [15]; using t-butyl 
hydroperoxide as the substrate, the activity was mea-
sured as NADPH consumption at 340 nm. GR activity 
was determined using the method described by Glatzle 
et al. [16], which is based on NADPH oxidation and 
GSSG reduction. GST activity was measured according 
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to Habig et al. [17], with 1-chloro-2,4-dinitrobenzene 
and glutathione used as substrates and monitoring the 
increase in absorbance at 340 nm [17].
Determination of the concentrations of TBARS 
and -SH groups
The level of lipid peroxidation in kidney was estimated 
according to the method described by Rehncrona et al. 
[18]. A mixture of equal volumes of the sample and 0.6% 
2-thiobarbituric acid were heated at 95°C for 10 min. 
After interrupting the reaction at 0°C for 10 s, the absor-
bance at 532 nm was measured. TBARS concentration 
was determined using malondialdehyde as a standard.
The concentrations of total -SH groups were mea-
sured according to Ellman’s protocol customized for 
microtiter plate [19]. Samples were mixed with Ellman’s 
reagent (5,5’-dithiobis-(2-nitrobenzoic acid)) and after 
10 min the absorbance at 412 nm was measured. For 
determination of non-protein -SH groups, proteins 
were precipitated by the addition of a sulfosalicylic acid.
Protein determination
Protein concentrations in kidney samples were mea-
sured by the method of Lowry [20] using bovine serum 
albumin as a standard.
Preparation for histological analysis
After the kidney samples were dehydrated by increasing 
the concentrations of ethanol and xylol, each sample was 
embedded in Histowax (Histolaboduct AB, Göteborg, 
Sweden) and cut into 5-μm sections on a rotary micro-
tome (Leica, Germany). Preparation for Hematoxylin 
Eosin (H&E) staining included deparaffinization in 
xylol, rehydration using decreasing concentrations of 
ethanol in water and finally staining with hematoxylin 
and eosin (H&E) stain [21]. Digital images of kidney 
tissue were captured using a Leica DM LS2 light mi-
croscope and Canon PowerShot S70 camera.
Qualitative analysis of the kidney
Qualitative H&E analysis included histomorphological 
examination of the kidney cortex (epithelial cells of 
renal proximal tubules, shape of the tubular lumens, 
morphology of glomeruli) and medulla. The shape 
of the tubular lumen is a direct consequence of size, 
especially the water content of the epithelial cells lin-
ing the tubule lumen. When the cells are of normal 
volume, the lumen of the tubule assumes a round or 
oval shape. When the volume of the cells is increased, 
the lumen assumes an irregular, stellate appearance. 
A semi-quantitative method for describing shape and 
visibility of epithelial cell nuclei was used to classify 
them as either (i) normal and rounded and clearly 
visible, or (ii) rounded, less visible or focally absent.
The described morphological changes were classi-
fied as ‘slightly abnormal’ when the shape of the tubular 
lumen was regular (oval or round) in at least 75% of 
all examined tubules, and when rounded nuclei were 
present in all cells but were poorly visible in less than 
50% of all examined tubules. Morphological changes 
were classified as ‘moderately abnormal’ when (i) the 
proportion was reversed and the shape of the lumen 
tubules was regular (oval or round) in up to 20% of 
all examined tubules, and in up to 75% the shape of 
the tubules was stellate, and also when (ii) the nuclei 
were rounded and poorly visible in at least 50% of all 
examined cells, and were focally-absent in less than 
50% of all tubules.
Urinalysis
The presence of RBC and WBC, glucose, bilirubin, 
ketones and nitrite in the urine, the pH, specific gravity 
and concentrations of total proteins (g/L), urobilinogen 
(I.U.) and ascorbic acid (mmol/L) were determined 
using commercial Uriscan urine strips, YD Diagnostics 
(Yongin, Republic of Korea).
Data analysis and statistical procedures
Statistical analyses were performed according to the 
protocols described by Hinkle et al. [22]. During sta-
tistical processing of the results, it was shown that there 
were no differences between control groups Cont6 and 
Cont24, and they were merged and represented as one 
control group, Cont. Therefore, the activities of anti-
oxidant enzymes, GST, the concentration of TBARS, 
total and non-protein free -SH groups were compared 
by one-way ANOVA and Tukey’s HSD post hoc test. 
Values were expressed as the mean±standard error of 
the mean (SEM) and the significance level was p<0.05.
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RESULTS
The activity of SOD1 was increased at 6 h af-
ter administration of the low dose of ibogaine 
(group L6 – 1 mg/kg b.w.) as compared to 
the control, and it remained elevated after 24 
h (L24) (Fig. 1A). There was no statistically 
significant difference between the higher 
dose of ibogaine (groups H6 and H24) as 
compared to the control. On the other hand, 
GR activity (Fig.1E) was decreased at 6 h 
after administration of both doses (com-
pared to the control), and decreased activity 
persisted after 24 h. No changes in SOD2, 
GSH-Px and GST activities after ibogaine 
application were observed (Fig. 1B, D, F, 
respectively), regardless of the dosage and 
time. Although a general increase in GSH-
Px was observed when a dose of 20 mg/kg 
b.w. was administered, neither ANOVA nor 
post-hoc test showed statistical significance 
(p=0.0532) with respect to the control. The 
differences between the treated animals and 
the control were not statistically significant 
when catalase activity was examined (Fig. 
1C). There were no changes in the concen-
tration of TBARS, total and non-protein 
-SH groups in any of the treated group as 
compared to the control (Fig. 2).
Histological analysis of the kidney 
showed visible changes of slight and mod-
erate intensities in animals treated with 
ibogaine, while in animals from the con-
trol group no changes were detected (Fig. 
3). The proportion of moderate changes 
compared to slight changes was elevated 
at 24 h after treatment with both doses 
(Fig. 4). The effect was more visible for the 
higher dose. Dystrophic changes are vis-
ible in the epithelial cells of renal proximal 
tubules located adjacent to the glomeruli. 
The lumens of the tubules had an irregular 
stellate shape, due to the increase in vol-
ume of tubular cells. Voluminous tubular 
cells had a cytoplasm with a characteristic 
granular appearance due to the presence 
of a large number of acidophilus granules 
corresponding to enlarged mitochondria. 
Fig. 1. Activity of enzymes in rat kidney. A – superoxide dismutase 1 (SOD1); B – 
superoxide dismutase 2 (SOD2); C – catalase (CAT); D – glutathione peroxidase 
(GSH-Px); E – glutathione reductase (GR); F – glutathione S-transferase (GST). 
Results are expressed as the mean±SEM. Statistical significance was calculated 
by one-way ANOVA (p<0.05, F values are presented) and post hoc compared by 
Tukey’s HSD test (p<0.05); *** – p<0.001; ** – p<0.01; * – p<0.05. Cont – control 
group, L – groups treated with ibogaine 1 mg/kg b.w., H – groups treated with 20 
mg/kg b.w.; numbers 6 and 24 indicate the times (h) after ibogaine administration.
Fig. 2. Concentrations of TBARS (A), total -SH groups (B) and non-protein -SH 
groups (C) in rat kidney. Results are expressed as the mean±SEM. Statistical sig-
nificance was calculated by one-way ANOVA (p<0.05, F values are presented). 
Cont – control group, L – groups treated with ibogaine 1 mg/kg b.w., H – groups 
treated with 20 mg/kg b.w.; numbers 6 and 24 indicate the times (h) after ibogaine 
administration.
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Cell nuclei were rounded, less visible or focally absent. 
The borders between voluminous individual cells were 
less clear. The majority of glomeruli as well as the renal 
interstitium were without morphological changes.
Urine analysis showed no presence of RBCs, WBCs, 
glucose, bilirubin, ketones or nitrite in either the treated 
groups or the control. The concentrations of total 
proteins, urobilinogen and ascorbic acid, as well as 
the pH value and specific gravity were not different 
in the treated groups when compared to the control 
(data not shown).
DISCUSSION
Although ibogaine can act as a pro-antioxidant, pro-
moting increased antioxidant activity in a dose- and 
time-dependent manner in different in vitro and ex vivo 
model systems, including yeast [7] and human eryth-
rocytes [8], our recent in vivo findings [6] showed that 
ibogaine treatment influenced hepatic redox homeostasis, 
but not to a sufficient extent to remodel antioxidant 
enzyme activities at 6 and 24 h post ibogaine applica-
tion. However, in vitro and ex vivo experiments were 
performed with much higher doses than used in vivo 
and per os application, where its pro-antioxidant ability 
in the liver was not as convincing [6]. Results showed 
that in vivo intragastric application in rats and mice led 
to much lower ibogaine and noribogaine concentrations 
in blood plasma [6,12] when compared to doses used in 
vitro. Therefore, the pro-antioxidant role of ibogaine was 
questioned. Here we explored the effect of ibogaine on 
the kidneys, which are energetically very active, with a 
Fig. 3. Representative micrographs showing kidney morphology 
in control group and groups treated with ibogaine (H&E, 400x). 
A – Kidney cortex with preserved glomeruli, normal epithelial 
cells and round or oval lumen of proximal tubules; B, D, F, H – 
slight changes (the lumen of proximal tubules are round or oval, 
while the volume of the tubular cells is slightly increased; nuclei 
are focally less visible); C, E, G, I – moderate changes (the lumen 
of proximal tubules are irregular, stellate, while the volume of the 
tubular cells is markedly increased; nuclei are less visible or focally-
absent). Cont – control group, L – groups treated with ibogaine 
1 mg/kg b.w., H – groups treated with 20 mg/kg b.w.; numbers 6 
and 24 indicate the times (h) after ibogaine administration; g – 
glomerulus, * – lumen of proximal tubule, ↑ – nucleus.
Fig. 4. Morphological changes in kidney. Number of animals with 
slight and moderate changes at the level of proximal tubules and 
tubular epithelial cells. Cont – control group, L – groups treated 
with ibogaine 1 mg/kg b.w., H – groups treated with 20 mg/
kg b.w., numbers 6 and 24 indicate the times (h) after ibogaine 
administration.
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high metabolism. Kidneys are prone to oxidative stress 
and acute kidney injury has a mitochondrial and ROS 
origin [23]. It was also shown that redox disturbances can 
contribute to renal morphologic alterations in proximal 
tubules in rats treated with antipsychotic drugs [24]. After 
ingestion, ibogaine is rapidly converted to noribogaine 
and excreted via the kidneys and the gastrointestinal 
system [25,26]. It was shown that ibogaine is present 
in mice kidneys 4 h after per os application and that it 
was relatively rapidly converted to noribogaine [27]. 
However, in our experiment, GST activity was no dif-
ferent from the control, suggesting ordinary xenobiotic 
metabolic activity. Kubiliene et al. [12] determined the 
pharmacokinetic properties of ibogaine and noribogaine 
in mice tissues after intragastral application of 26.3 
mg/kg of ibogaine. The authors established that the 
kidneys were systematically exposed to ibogaine that 
is rapidly metabolized to noribogaine [12]. A similar 
result was reported in mice treated intragastrally and in 
human postmortem studies [27,28]. Although kidneys 
metabolize ibogaine, our results showed no changes 
in total GST activity, suggesting no difference in the 
overall microsomal xenobiotics metabolism in kidneys 
and the absence of extreme conditions that could led 
to oxidative stress from this origin.
The increased activity of SOD1 at 6 and 24 h after 
application of a dose of 1 mg/kg b.w. suggests oxida-
tive pressure from the increased amount of superox-
ide. Additionally, GR activity was also lower after 6 
and 24 h, indicating a compensatory decrease in the 
glutathione-dependent antioxidant pathway, as basic 
antioxidant defense was provided by the SOD-CAT 
axis. The decrease in GR activity could be the conse-
quence of the decline in available NADPH due to the 
effect of ibogaine on ATP pool depletion and overall 
drain in cellular energy. However, GR activity was 
also decreased after 6 and 24 h when the animals were 
treated with 20 mg/kg b.w. It would appear that the 
decrease in GR activity observed for both doses and 
time points was a reflection of NADPH unavailability 
after ibogaine application. Additionally, it could be a 
compensatory decline in NADPH consumption that 
lasted until cellular glucose metabolism homeostasis 
was restored and a stable homeostatic energy level was 
reestablished. There were no changes in -SH groups 
after ibogaine treatment, which indicates preserved thiol 
redox homeostasis. Although there were no changes 
in TBARS levels (as an indication of oxidative stress 
at the level of lipid peroxides), morphological changes 
were observed (and rated as slight to moderate) at 24 
h after ibogaine treatment.
Histological analysis indicated higher mitochondrial 
activity, which was in accordance with the postulated 
elevation of ROS production, mainly of superoxide, that 
coincided with elevation in SOD activity. Histological 
analyses suggest that compensatory elevation of SOD1 
activity after 6 h (at the level of the whole kidney) was 
insufficient to prevent the damage to epithelial cells 
observed after 24 h (which could be of prooxidative 
origin). Cells of the proximal tubule require intense ATP 
production to reabsorb solutes through active transport. 
Furthermore, ATP supports cell-surface ATPase activity 
which prevents cell swelling due to the passive entry 
of sodium ions and water. If ibogaine depleted ATP, 
regular ionic homeostasis was disturbed and the mito-
chondria were activated to produce ATP. Mitochondrial 
morphology is dependent on the cell’s requirement 
for energy, and different mitochondrial and energetic 
states have been linked with acute kidney injury [23]. 
However, there were no differences in urine parameters 
between control and ibogaine-treated animals. The 
concentrations of bilirubin and urobilinogen as well as 
urine-specific density showed no signs of kidney and 
liver damage. Blood cells and proteins due to kidney 
damage (tubulopathy and glomerulopathy) were not 
present in the urine, and neither were RBCs or WBCs 
due to urinary tract damage. Glucose in urine could be 
the consequence of high blood glucose concentration 
and/or kidney damage; however, our recent results 
showed that there was no difference in blood glucose 
concentration between control and ibogaine-treated 
animals [6]. The absence of nitrite and WBCs in the 
urine showed that there were no signs of kidney or 
urinary tract infection. The nutritive status of rats was 
also confirmed as normal as judged by the concentration 
of ascorbic acid, pH and absence of ketone bodies after 
ibogaine treatment. Hence, there were no indicators of 
elevated utilization of fats instead of glucose, ingestion 
of ascorbic acids, starvation or metabolic discomfort 
such as diarrhea or tubular acidosis.
CONCLUSION
In vivo application of 1 mg/kg ibogaine elevated SOD1 
activity, which was followed by a decrease in GR ac-
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tivity in kidneys. GR activity was also decreased after 
application of 20 mg/kg, suggesting disturbed redox 
homeostasis. Normal urinalysis results after ibogaine 
treatment revealed that kidney function was not mea-
surably affected. Treatment with both doses of ibogaine 
provoked moderate changes in kidney morphology 
after 24 h, indicating a precautionary assessment of 
kidney activity during and after ibogaine use.
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